COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04907331; 2021-002171-19 AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma Bánki Z, EBioMedicine, 2022 HEVACC Full text Commentary |
RNA based vaccine |
1 dose ChAdOx1/ 1 dose BNT162b2 |
ChAdOx1 |
RCTPhase 2 | Healthy adults with no history of COVID-19 in 3 centres in Austria. | N= 234 |
Some concerns Details |
|
|
ISRCTN69254139, EudraCT: 2020-005085-33 AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma Liu X, Lancet, 2022 Com-COV Full text Full text Commentary Commentary |
RNA based vaccine |
1 dose ChAdOx1/ 1 dose BNT162b2 1 dose BNT162b2 /1 dose ChAdOx1 |
2 doses ChAdOx1 2 doses BNT162b2 |
RCTPhase 2 | Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK | N= 463 |
Some concerns Details |
|